2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111603
    Calcium dobesilate 20123-80-2 99.82%
    Calcium dobesilate is a vascular protector with oral activity that can clear hydroxyl free radicals, with an IC50 of 1.1 pM. Calcium dobesilate has antioxidant activity and helps to reduce oxidative stress and inflammation in the retinas of diabetic mice. Calcium dobesilate can be used to study chronic venous diseases, diabetic retinopathy, and the occurrence of hemorrhoids, among other conditions.
    Calcium dobesilate
  • HY-113005
    Glutarylcarnitine 102636-82-8
    Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine
  • HY-113082
    L-Thyronine 1596-67-4 98.91%
    L-Thyronine is a deiodinated thyroxine.
    L-Thyronine
  • HY-113217
    Cholesteryl oleate 303-43-5 ≥99.0%
    Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing.
    Cholesteryl oleate
  • HY-113435
    8-Dehydrocholesterol 70741-38-7
    8-Dehydrocholesterol elevated concentration is one of the diagnostic biochemical hallmarks of classical Smith-Lemli-Opitz syndrome (SLOS).
    8-Dehydrocholesterol
  • HY-117095
    4-Methylumbelliferyl oleate 18323-58-5 ≥98.0%
    4-Methylumbelliferyl oleate is a fluorogenic substrate for acid and alkaline lipases. 4-Methylumbelliferyl oleate is cleaved by lipases, liberating 4-Methylumbelliferyl (Ex/Em=320/450 nm).
    4-Methylumbelliferyl oleate
  • HY-117391
    AZ-Dyrk1B-33 1679330-37-0 ≥99.0%
    AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC50 of 7 nM.
    AZ-Dyrk1B-33
  • HY-122308
    Militarine 58139-23-4 99.83%
    Militarine, a glycosidic compound isolated from Bletilla striata, exhibits plant growth-inhibitory activity.
    Militarine
  • HY-123046
    AS1708727 1253226-93-5 99.44%
    AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively.
    AS1708727
  • HY-126855
    Cholic acid 7-sulfate 60320-05-0 ≥99.0%
    Cholic acid 7-sulfate (7-Sulfocholic acid), a metabolite of Cholic acid, is a Takeda G-protein receptor 5 (TGR5) agonist. Cholic acid 7-sulfate can increase Tgr5 expression and induce GLP-1 secretion.
    Cholic acid 7-sulfate
  • HY-128741
    D-Allose 2595-97-3 99.85%
    D-Allose is an endogenous metabolite.
    D-Allose
  • HY-129974
    3,3'-Diiodo-L-thyronine 4604-41-5
    3,3'-Diiodo-L-thyronine (3,3'-T2) is an endogenous metabolite of thyroid hormone. 3,3'-Diiodo-L-thyronine significantly enhances COX activity.
    3,3'-Diiodo-L-thyronine
  • HY-133680
    β-Tocopherol 16698-35-4 99.64%
    β-Tocopherol is an analogue of vitamin E, exhibits antioxidant properties. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol.
    β-Tocopherol
  • HY-136497
    Coenzyme FO 37333-48-5 99.06%
    Coenzyme FO, a deazaflavin chromophore, acts as an important hydride acceptor/donor in the central methanogenic pathway.
    Coenzyme FO
  • HY-141699
    FATP1-IN-1 1431945-95-7 99.55%
    FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively.
    FATP1-IN-1
  • HY-143312
    V-0219 878453-71-5 98.65%
    V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research.
    V-0219
  • HY-145001
    20-HC-Me-Pyrrolidine
    20-HC-Me-Pyrrolidine is a potent Aster protein inhibitor with IC50s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER).
    20-HC-Me-Pyrrolidine
  • HY-147372
    SJ000063181 945189-68-4 98.92%
    SJ000063181 is a potent BMP signaling activator with an EC50 ≤1 µM. SJ000063181 can be used as chemical probes to interrogate BMP signaling due to it can penetrate zebrafish embryos.
    SJ000063181
  • HY-162351
    EBP-IN-1 99.67%
    EBP-IN-1 (compound 11) is an inhibitor of emopamil-binding protein (EBP), a sterol isomerase in the cholesterol biosynthetic pathway. EBP-IN-1 has a long half-life in rodents and has good metabolic turnover and brain penetration properties. EBP-IN-1 enhances oligodendrocyte formation in human cortical organoids.
    EBP-IN-1
  • HY-19627A
    Naldemedine tosylate 1345728-04-2
    Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine tosylate is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
    Naldemedine tosylate
Cat. No. Product Name / Synonyms Application Reactivity